Oncolytics Biotech (TSE:ONC) Stock Price Passes Above 200-Day Moving Average – Here’s What Happened

Oncolytics Biotech Inc. (TSE:ONC) crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of C$7.61 and traded as high as C$14.90. Oncolytics Biotech shares last traded at C$14.90, with a volume of 280 shares.

Analyst Ratings Changes

Separately, Lake Street Capital raised Oncolytics Biotech to a “strong-buy” rating in a research report on Wednesday, August 13th. One equities research analyst has rated the stock with a Strong Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, Oncolytics Biotech currently has an average rating of “Buy”.

Oncolytics Biotech Stock Performance

The firm has a fifty day simple moving average of C$14.90 and a 200-day simple moving average of C$7.61. The company has a quick ratio of 8.86, a current ratio of 2.99 and a debt-to-equity ratio of 11.75. The company has a market cap of C$1.50 billion, a PE ratio of -40.27 and a beta of 0.80.

Oncolytics Biotech (TSE:ONC) last announced its earnings results on Wednesday, November 12th. The company reported C($0.14) earnings per share (EPS) for the quarter. On average, research analysts forecast that Oncolytics Biotech Inc. will post -0.41 EPS for the current fiscal year.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.